dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Dieras, Veronique |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Patt, Debra |
dc.contributor.author | Wildiers, Hans |
dc.contributor.author | O’Shaughnessy, Joyce |
dc.contributor.author | Zamora Adelantado, Esther |
dc.contributor.author | Rugo, Hope |
dc.date.accessioned | 2021-10-19T10:12:12Z |
dc.date.available | 2021-10-19T10:12:12Z |
dc.date.issued | 2020-11 |
dc.identifier.citation | Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O’Shaughnessy J, et al. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1. Breast Cancer Res Treat. 2020 Nov;184:161-72. |
dc.identifier.issn | 1573-7217 |
dc.identifier.uri | https://hdl.handle.net/11351/6406 |
dc.description | Abemaciclib; Càncer de mama metastàsic; Supervivència global |
dc.description.sponsorship | This study was funded by Eli Lilly and Company. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Breast Cancer Research and Treatment;184 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Quimioteràpia |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.title | Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s10549-020-05838-5 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1007/s10549-020-05838-5 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Rugo HS] Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. [Dieras V] Centre Eugene Marquis UNICANCER, Rennes Cedex, France. [Cortes J] 3 IOB Institute of Oncology, Quironsalud Group, Madrid, Spain. 4 IOB Institute of Oncology, Quironsalud Group, Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Patt D] Texas Oncology, Austin, TX, USA. US Oncology, Dallas, TX, USA. [Wildiers H] Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium. [O'Shaughnessy J] Texas Oncology, US Oncology, Baylor University Medical Center, Dallas, TX, USA. [Zamora E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 32789591 |
dc.identifier.wos | 000559209800002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |